Back to search

Peptide record

TPDB01088

LL 37 Antibacterial Anticancer Antifungal Antioxidant Antiparasitic Antiviral Cell-penetrating Peptides Hemolysis Toxicity standard
37 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB01088
LL 37
Antibacterial Anticancer Antifungal Antioxidant Antiparasitic Antiviral Cell-penetrating Peptides Hemolysis Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides Delivery and barrier-penetrating peptides Functional / health-promoting peptides
AntiBP3 dbAMP DRAMP Peptipedia AntiCP 2.0 CancerPPD 2.0 SATPdb dbACP iACP-DRLF Antifungipept CAFPdb dbAMP 3.0 i2APP AI4AVP AVPpred-BWR DRAVP 2.0 CPPsite3.0 APD_complete APD_hemolytic HemoPI Hemolytic2 PD_Hemolysis
standard
No
A 37-aa standard natural multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from AntiBP3, dbAMP, DRAMP, and other sources, with an available 3D structural model.
Sequence
LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES
Physicochemical Analysis
C205H340N60O53
ACHMWY
K
4493.32
11.10
11
5
13
+6
12.83
-0.724
89.46
Mammalian: 5.5 hour Yeast: 3 min E.coli: 2 min
0
0.00
5
Residue Composition
number
0
A
5
R
1
N
2
D
0
C
3
E
1
Q
2
G
0
H
3
I
4
L
6
K
0
M
4
F
1
P
2
S
1
T
0
W
0
Y
2
V
Amino Acid Distribution
A: 0 R: 5 N: 1 D: 2 C: 0 E: 3 Q: 1 G: 2 H: 0 I: 3 L: 4 K: 6 M: 0 F: 4 P: 1 S: 2 T: 1 W: 0 Y: 0 V: 2
Chemical Descriptors
37
C205H340N60O53
4493.32
11.10
+6
12.83
-0.724
Free
L
Cationic
Linear
Linear
Free
Antimicrobial
Also known human cathelicidin
N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CO)C(=O)O
Evidence Records 25 records
Evidence 1 Activity

Activity

MIC
Antibacterial
1.5 µg/mL

Target

L. monocytogenes EGD

Source & Reference

dbAMP DRAMP

Other

Source Activity Label Source Definition
Antibacterial
dbAMP classified as Antibacterial under the Anti-bacterial function class. DRAMP antibacterial activity supported by MIC records against bacterial target organisms.
nt), B. subtilis, S. mutans, M. tuberculosis (anti-TB), M. smegmatis, M. bovis, L. casei, L. monocytogenes EGD (MIC 1.5 ug/ml), M. luteus, P. acnes, T. denticola, T. palidum, Y. pestis, A. xylosoxidans, B. suis, F. n
Evidence 2 Activity

Activity

LC50
LC50= 21 at 100 µM
Anticancer
21

Target

Breast Cancer
MCF-7
Breast

Assay & Model

MTT/MTS assay
72-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2014

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation. dbAMP 3.0 classified as Anticancer under the disease-associated peptide function classes.
Evidence 3 Activity

Activity

LC50
LC50= 27 at 100 µM
Anticancer
27

Target

Prostate cancer
LNCaP
Prostate

Assay & Model

MTT/MTS assay
72-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2014
Evidence 4 Activity

Activity

LC50
LC50= 24 at 100 µM
Anticancer
24

Target

Ovarian Cancer
OVRCAR-3
Ovary

Assay & Model

MTT/MTS assay
72-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2014
Evidence 5 Activity

Activity

MIC
Antifungal
1.5 µg/mL

Target

L. monocytogenes EGD

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

Source Activity Label Source Definition
Antifungal
dbAMP classified under the Anti-fungal function class. DRAMP antifungal activity supported by activity records against fungal target organisms.
nt), B. subtilis, S. mutans, M. tuberculosis (anti-TB), M. smegmatis, M. bovis, L. casei, L. monocytogenes EGD (MIC 1.5 ug/ml), M. luteus, P. acnes, T. denticola, T. palidum, Y. pestis, A. xylosoxidans, B. suis, F. n
Evidence 6 Activity

Activity

MIC
Antiparasitic
1.5 µg/mL

Target

L. monocytogenes EGD

Source & Reference

dbAMP 3.0 DRAMP

Other

Source Activity Label Source Definition
Antiparasitic
DRAMP antiparasitic activity supported by activity records against parasitic targets. dbAMP 3.0 classified under the Anti-parasitic function class.
nt), B. subtilis, S. mutans, M. tuberculosis (anti-TB), M. smegmatis, M. bovis, L. casei, L. monocytogenes EGD (MIC 1.5 ug/ml), M. luteus, P. acnes, T. denticola, T. palidum, Y. pestis, A. xylosoxidans, B. suis, F. n
Evidence 7 Activity

Activity

MIC
Antiviral
1.5 µg/mL

Target

L. monocytogenes EGD

Source & Reference

dbAMP 3.0 DRAMP DRAVP 2.0

Other

Source Activity Label Source Definition
Antiviral
DRAMP antiviral activity supported by activity records against viral targets. dbAMP 3.0 classified under the Anti-viral function class.
nt), B. subtilis, S. mutans, M. tuberculosis (anti-TB), M. smegmatis, M. bovis, L. casei, L. monocytogenes EGD (MIC 1.5 ug/ml), M. luteus, P. acnes, T. denticola, T. palidum, Y. pestis, A. xylosoxidans, B. suis, F. n
Evidence 8 Activity

Activity

Cell-penetrating Peptides

Target

HeLa Cells

Source & Reference

CPPsite3.0
CPPsite3

Other

Source Activity Label Source Definition
Cell-penetrating Peptides
CPPsite3.0 experimentally validated cell-penetrating peptide annotation.
Natural residues Linear L Cationic
Protein derived
EGFP protein
Cytoplasm
EGFP‐CAT 2‐8‐times higher intensity than other derivative and 3‐6 times higher than EGFP‐LL37, EGFP‐IL, EGFP‐L‐K6, and EGFP‐TAT
In vitro
CCHHHHHHHHHHHHHHHHHHHHHHHHHHTTTTTCCCC
Evidence 9 Activity

Activity

% Hemolysis
Hemolysis
0.7 %
[Ref.29859288] 2.9 ± 0.7% Hemolysis at 500µg/ml against human red blood cell

Source & Reference

Hemolytik APD_complete APD_hemolytic PD_Hemolysis
DRAMP4
Gene. 2018 May 30. pii: S0378-1119(18)30617-6.

Other

Source Activity Label Source Definition
Hemolysis
APD_complete APD-derived hemolytic peptide annotation. APD_hemolytic APD hemolytic peptide annotation. Hemolytik experimentally validated hemolytic peptide annotation.
Evidence 10 Activity

Activity

50% Cytotoxicity
Toxicity
>50 µM
Cytotoxic
50% Cytotoxicity | >50 | µM | target cell: Human primary macrophages

Target

Human primary macrophages

Source & Reference

NA
DBAASP
Engineered Human Cathelicidin Antimicrobial Peptides Inhibit Ebola Virus Infection. | iScience | 2020
Evidence 11 Activity

Activity

7.1% Hemolysis
Toxicity
50 µM
Hemolytic Cytotoxic
7.1% Hemolysis | 50 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
A Rapid In Vivo Toxicity Assessment Method for Antimicrobial Peptides | Toxics | 2024
Evidence 12 Activity

Activity

LC50
Toxicity
30 µM
Cytotoxic
LC50 | 30 | µM | target cell: Human bronchial epithelial cells BEAS-2B

Target

Human bronchial epithelial cells BEAS-2B

Source & Reference

NA
DBAASP
A Rapid In Vivo Toxicity Assessment Method for Antimicrobial Peptides | Toxics | 2024
Evidence 13 Activity

Activity

LC
Toxicity
50 µM
Cytotoxic
LC | 50 | µM | target cell: Human bronchial epithelial cells BEAS-2B

Target

Human bronchial epithelial cells BEAS-2B

Source & Reference

NA
DBAASP
A Rapid In Vivo Toxicity Assessment Method for Antimicrobial Peptides | Toxics | 2024
Evidence 14 Activity

Activity

1% Hemolysis
Toxicity
<6.3 µM
Hemolytic Cytotoxic
1% Hemolysis | <6.3 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Characterisation and evaluation of synthetic antimicrobial peptides against Bacillus globigii, Bacillus anthracis and Burkholderia thailandensis. | Int J Antimicrob Agents | 2010
Evidence 15 Activity

Activity

10% Hemolysis
Toxicity
6.7 µM
Hemolytic Cytotoxic
10% Hemolysis | 6.7 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Prokaryotic selectivity and LPS-neutralizing activity of short antimicrobial peptides designed from the human antimicrobial peptide LL-37 | Peptides | 2012
Evidence 16 Activity

Activity

17% Hemolysis
Toxicity
80 µg/mL
Hemolytic Cytotoxic
17% Hemolysis | 80 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Evaluation of the inactivation of infectious Herpes simplex virus by host-defense peptides. | Eur J Clin Microbiol Infect Dis | 2000
Evidence 17 Activity

Activity

50% Hemolysis
Toxicity
43.5 µg/mL
Hemolytic Cytotoxic
50% Hemolysis | 43.5 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Anti-tuberculosis activity of ?-helical antimicrobial peptides: de novo designed L- and D-enantiomers versus L- and D-LL-37. | Protein Pept Lett | 2011
Evidence 18 Activity

Activity

Toxicity
Cytotoxic
NA | target cell: Murine macrophage cells J774A.1

Target

Murine macrophage cells J774A.1

Source & Reference

NA
DBAASP
Cathelicidin is involved in the intracellular killing of mycobacteria in macrophages. | Cell Microbiol | 2011
Evidence 19 Activity

Activity

Toxicity
Cytotoxic
NA | target cell: Human dermal fibroblasts

Target

Human dermal fibroblasts

Source & Reference

NA
DBAASP
Collagen tethering of synthetic human antimicrobial peptides cathelicidin LL37 and its effects on antimicrobial activity and cytotoxicity. | Acta Biomater | 2017
Evidence 20 Activity

Activity

MEC
Toxicity
12 µM
Cytotoxic
MEC | 12 | µM | target cell: Human PBMC

Target

Human PBMC

Source & Reference

NA
DBAASP
Application of Antimicrobial Peptides of the Innate Immune System in Combination With Conventional Antibiotics-A Novel Way to Combat Antibiotic Resistance? | Front Cell Infect Microbiol | 2019
Evidence 21 Activity

Activity

MEC
Toxicity
10 µM
Cytotoxic
MEC | 10 | µM | target cell: Human neutrophils

Target

Human neutrophils

Source & Reference

NA
DBAASP
Application of Antimicrobial Peptides of the Innate Immune System in Combination With Conventional Antibiotics-A Novel Way to Combat Antibiotic Resistance? | Front Cell Infect Microbiol | 2019
Evidence 22 Activity

Activity

MEC
Toxicity
>20 µM
Cytotoxic
MEC | >20 | µM | target cell: Murine peritoneal macrophages

Target

Murine peritoneal macrophages

Source & Reference

NA
DBAASP
Application of Antimicrobial Peptides of the Innate Immune System in Combination With Conventional Antibiotics-A Novel Way to Combat Antibiotic Resistance? | Front Cell Infect Microbiol | 2019
Evidence 23 Activity

Activity

20% Cytotoxicity
Toxicity
5 µM
Cytotoxic
20% Cytotoxicity | 5 | µM | target cell: Human Primary Epidermal Keratinocytes (HEK)

Target

Human Primary Epidermal Keratinocytes (HEK)

Source & Reference

NA
DBAASP
Comparison of Anti-Viral Activity of Frog Skin Anti-Microbial Peptides Temporin-Sha and [K³]SHa to LL-37 and Temporin-Tb against Herpes Simplex Virus Type 1. | Viruses | 2019
Evidence 24 Activity

Activity

% Hemolysis
Toxicity
0.7 %
Hemolytic
Hemolytic_activity: [Ref.29859288] 2.9 ± 0.7% Hemolysis at 500µg/ml against human red blood cell

Target

erythrocytes

Source & Reference

NA
DRAMP
Gene. 2018 May 30. pii: S0378-1119(18)30617-6.
Evidence 25 Hemolysis

Activity

0.7 %
% Hemolysis
[Ref.29859288] 2.9 ± 0.7% Hemolysis at 500µg/ml against human red blood cell
Hemolysis

Source & Reference

APD_complete APD_hemolytic HemoPI PD_Hemolysis
Gene. 2018 May 30. pii: S0378-1119(18)30617-6.
DRAMP4
APD_complete APD_hemolytic PD_Hemolysis

Other

Source Activity Label Source Definition
Hemolysis
APD_complete APD-derived hemolytic peptide annotation. APD_hemolytic APD hemolytic peptide annotation.
Additional Detail Fields 1 fields
CCHHHHHHHHHHHHHHHHHHHHHHHHHHTTTTTCCCC